ATE316976T1 - O-aryl glucosid sglt2 inhibitoren und verfahren - Google Patents

O-aryl glucosid sglt2 inhibitoren und verfahren

Info

Publication number
ATE316976T1
ATE316976T1 AT01922840T AT01922840T ATE316976T1 AT E316976 T1 ATE316976 T1 AT E316976T1 AT 01922840 T AT01922840 T AT 01922840T AT 01922840 T AT01922840 T AT 01922840T AT E316976 T1 ATE316976 T1 AT E316976T1
Authority
AT
Austria
Prior art keywords
methods
sglt2 inhibitors
aryl glucoside
glucoside sglt2
aryl
Prior art date
Application number
AT01922840T
Other languages
English (en)
Inventor
William N Washburn
Philip M Sher
Gang Wu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22712264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE316976(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE316976T1 publication Critical patent/ATE316976T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01922840T 2000-03-30 2001-03-29 O-aryl glucosid sglt2 inhibitoren und verfahren ATE316976T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19309400P 2000-03-30 2000-03-30

Publications (1)

Publication Number Publication Date
ATE316976T1 true ATE316976T1 (de) 2006-02-15

Family

ID=22712264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01922840T ATE316976T1 (de) 2000-03-30 2001-03-29 O-aryl glucosid sglt2 inhibitoren und verfahren

Country Status (21)

Country Link
US (1) US6683056B2 (de)
EP (1) EP1268502B1 (de)
JP (1) JP4986202B2 (de)
KR (1) KR100798203B1 (de)
CN (1) CN1275977C (de)
AT (1) ATE316976T1 (de)
AU (2) AU2001249598B2 (de)
BR (1) BR0109326A (de)
CA (1) CA2404373A1 (de)
DE (1) DE60117012T2 (de)
ES (1) ES2258079T3 (de)
HK (1) HK1049168A1 (de)
HU (1) HUP0301513A3 (de)
IL (1) IL151473A0 (de)
MX (1) MXPA02009522A (de)
NO (1) NO20024642L (de)
NZ (1) NZ520822A (de)
PL (1) PL365176A1 (de)
RU (1) RU2269540C2 (de)
WO (1) WO2001074834A1 (de)
ZA (1) ZA200207030B (de)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
KR100660738B1 (ko) * 2000-03-17 2006-12-22 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실록시 벤질벤젠 유도체, 그것을 함유하는의약조성물 및 그 제조중간체
IL155071A0 (en) * 2000-09-29 2003-10-31 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medical compositions containing the same
EP1344780A4 (de) * 2000-11-30 2004-01-28 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzolderivate, medizinische zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte für deren herstellung
HU228915B1 (en) 2000-12-28 2013-06-28 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof
TWI255817B (en) * 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
ATE442148T1 (de) 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
JP4590159B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
WO2003000712A1 (fr) * 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe
WO2003011880A1 (fr) * 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
MXPA04009229A (es) * 2002-03-22 2004-11-26 Kissei Pharmaceutical Cristales derivados de glucopiranosiloxibencil benceno.
US7956041B2 (en) * 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
MXPA05001549A (es) * 2002-08-08 2005-05-05 Kissei Pharmaceutical Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion.
CA2478889A1 (en) 2002-08-09 2004-02-19 Taisho Pharmaceutical Co., Ltd. Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
JP4651934B2 (ja) * 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
EP1577317A4 (de) 2002-12-25 2007-05-09 Kissei Pharmaceutical Stickstoffhaltige heterocyclische derivate,medizinische zusammensetzungen, die diese enthalten, und deren medizinische verwendung
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
CN1761676A (zh) * 2003-04-01 2006-04-19 大正制药株式会社 杂芳基5－硫代－β－D－吡喃葡糖苷衍生物及含有该衍生物的糖尿病治疗药
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
UA86042C2 (en) * 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
CA2549022A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
CA2549015A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic c-glycosides
CA2549017A1 (en) * 2003-08-01 2005-02-10 Mona Patel Substituted indazole-o-glucosides
BRPI0413232B8 (pt) * 2003-08-01 2021-05-25 Mitsubishi Tanabe Pharma Corp composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
AU2004261664A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-O-glucosides
JP4568488B2 (ja) * 2003-09-05 2010-10-27 花王株式会社 イソプロピルメチルフェノール配糖体
EP1516665A1 (de) 2003-09-18 2005-03-23 Sony International (Europe) GmbH Verfahren zu der Immobilisierung und dem Spannen einer Nukleinsäure auf ein Substrat
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
DE10361133A1 (de) * 2003-12-22 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CN1934103B (zh) * 2004-03-04 2011-06-01 橘生药品工业株式会社 稠杂环衍生物，包含稠杂环衍生物的药物组合物及其医药用途
CA2557801C (en) 2004-03-16 2013-06-25 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
JPWO2005095372A1 (ja) * 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
CA2560005A1 (en) * 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. Phenol derivative, medicinal composition containing the same, and medicinal use thereof
TW200602335A (en) * 2004-03-31 2006-01-16 Kissei Pharmaceutical Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
US20050261292A1 (en) * 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1803729A4 (de) * 2004-09-29 2008-10-01 Kissei Pharmaceutical 1-(b-d-glycopyranosyl)-3-substituierte stickstoffhaltige heterocyclische verbindung, medizinische zusammensetzung, die diese enthält, und deren medizinische verwendung
DE102004058449A1 (de) * 2004-12-03 2006-06-14 Merck Patent Gmbh Tetrahydropyranderivate
WO2006064033A2 (en) 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
MY147375A (en) * 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
JP5073948B2 (ja) * 2005-01-31 2012-11-14 田辺三菱製薬株式会社 医薬組成物
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
ES2334940T3 (es) 2005-02-23 2010-03-17 Boehringer Ingelheim International Gmbh Derivados de ((hetero)ariletinilbencil)benceno sustituidos con glucopiranosilo y uso de los mismos como inhibidores del cotransportador 2 de glucosa dependiente de sodio (sglt2).
ATE453656T1 (de) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
ATE468347T1 (de) 2005-07-27 2010-06-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte ((hetero)cycloalyklethynyl-benzyl)- benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters (sglt)
UY29694A1 (es) * 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
US8507450B2 (en) 2005-09-08 2013-08-13 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
EP1989191B1 (de) 2006-02-15 2011-07-20 Boehringer Ingelheim International GmbH Glucopyranosyl-substituierte benzonitril-derivate, pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür
EP1854806A1 (de) * 2006-05-02 2007-11-14 MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thioglycoside als pharmaceutisch aktive Verbindungen
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2076503B1 (de) * 2006-05-19 2013-07-17 Taisho Pharmaceutical Co., Ltd C-phenylglycitolverbindung zur behandlung von diabetes
JP5230613B2 (ja) * 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
WO2007143052A1 (en) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TW200817424A (en) * 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
NZ577391A (en) * 2006-12-04 2011-11-25 Janssen Pharmaceutica Nv Thienyl-containing glycopyranosyl derivatives as antidiabetics
JP5330260B2 (ja) 2006-12-06 2013-10-30 スミスクライン ビーチャム コーポレーション 二環式化合物ならびに抗糖尿病薬としての使用
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
RU2492175C2 (ru) * 2007-04-02 2013-09-10 Теракос, Инк. Бензиловые производные гликозидов и способы их применения
WO2009014970A1 (en) 2007-07-26 2009-01-29 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
BRPI0815708B8 (pt) 2007-08-23 2021-05-25 Theracos Sub Llc composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
JP5596545B2 (ja) 2007-09-10 2014-09-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｓｇｌｔの阻害物質として有用な化合物の製造方法
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
JP5401465B2 (ja) * 2007-11-30 2014-01-29 ノバルティス アーゲー 有機化合物
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
WO2009096503A1 (ja) * 2008-01-31 2009-08-06 Daiichi Sankyo Company, Limited ベンジルフェニルグルコピラノシド誘導体
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
CA2725047A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
AU2009270936B2 (en) 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
ME02702B (de) 2008-08-22 2017-10-20 Theracos Sub Llc Verfahren zur herstellung von sglt2-hemmern
RS52236B (en) * 2008-08-28 2012-10-31 Pfizer Inc. DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CN101445527B (zh) * 2008-12-25 2011-09-14 天津药物研究院 五元芳杂环甲苯基葡萄糖苷、其制备方法和用途
EP2395983B1 (de) 2009-02-13 2020-04-08 Boehringer Ingelheim International GmbH Pharmazeutische zusammensetzung mit einem sglt2-inhibitor, einem dpp-iv-inhibitor und optional einem weiteren antidiabetischen mittel und ihre verwendung
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (de) 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. Kristallisationsverfahren für 1-(beta-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorphenyl)-2-thienylmethyl]benzol
MX2012002942A (es) 2009-09-30 2012-04-11 Boehringer Ingelheim Int Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno.
KR101813025B1 (ko) 2009-09-30 2017-12-28 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실­치환된 벤질­벤젠 유도체의 제조방법
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US9174971B2 (en) * 2009-10-14 2015-11-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
BR112012008924A2 (pt) 2009-10-20 2019-09-24 Novartis Ag derivado de glicosídeo e usos do mesmo
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
DK2496583T3 (en) 2009-11-02 2015-02-02 Pfizer Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US8586550B2 (en) 2010-06-18 2013-11-19 Green Cross Corporation Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
EP2697240B1 (de) 2011-04-14 2015-09-16 Novartis AG Glycosidderivate und ihre verwendung
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
ES2668045T3 (es) 2012-12-07 2018-05-16 Glycomimetics, Inc. Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
CN103127513A (zh) * 2013-03-11 2013-06-05 乔文龙 一种治疗糖尿病及并发症的α-糖苷酶抑制剂和羟甲基戊二酰辅酶A还原酶抑制剂组合物
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
EP2968375B1 (de) 2013-03-14 2019-06-12 MSD International GmbH Verfahren zur herstellung von sglt2-inhibitoren
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2906115T3 (es) 2013-04-18 2022-04-13 Boehringer Ingelheim Int Composición farmacéutica, métodos de tratamiento y usos de la misma
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
ES2951127T3 (es) 2014-01-23 2023-10-18 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales caninos
CN105001213B (zh) * 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
EP3227310B1 (de) 2014-12-03 2019-07-31 GlycoMimetics, Inc. Heterobifunktionelle inhibitoren von e-selektinen und cxcr4-chemokinrezeptoren
CN104478967A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含腈基苯噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104497068A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 一种含三氟甲氧基苯s-葡萄糖苷结构的化合物及其用途
CN104497074A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 一种含丙烯腈基和硝基苯o-葡萄糖苷结构化合物及用途
CN104497073A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 含丙烯腈和烷氧苯基o-葡萄糖苷结构的衍生物和用途
CN104497071A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 一种含丙烯腈基和腈基苯o-葡萄糖苷结构化合物及用途
CN104478961A (zh) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 含丙烯腈和胺基苯o-葡萄糖苷结构衍生物、其制备方法和用途
CN104497069A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 一类胺基苯基s-葡萄糖苷衍生物、其制备方法和用途
CN104497072A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 含丙烯腈和卤代苯o-葡萄糖苷结构衍生物、其制备方法和用途
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
US11045485B2 (en) 2016-01-22 2021-06-29 Glycomimetics, Inc. Glycomimetic inhibitors of PA-IL and PA-IIL lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
WO2018031445A1 (en) 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
JP7069136B2 (ja) 2016-10-07 2022-05-17 グリコミメティクス， インコーポレイテッド 極めて強力な多量体ｅ－セレクチンアンタゴニスト
EP3596096A1 (de) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl-derivate als e-selectin-antagonisten
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
WO2019133878A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
CN112955966A (zh) * 2018-06-14 2021-06-11 阿斯利康(英国)有限公司 用吉列净钠(gliflozin Sodium)-葡萄糖共转运剂2抑制剂医药组合物降低血糖的方法
KR20210034039A (ko) 2018-07-19 2021-03-29 아스트라제네카 아베 다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물
CN109456370A (zh) * 2018-12-24 2019-03-12 重庆理工大学 一种钠-葡萄糖协同转运蛋白2抑制剂及其应用
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US20220023252A1 (en) 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
EP4315350A1 (de) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systeme und verfahren zur verwaltung von prädiabetes mit einer pharmazeutischen gliflozin-natrium-glucose-cotransport-2-inhibitorzusammensetzung
CN113980071B (zh) * 2021-11-26 2023-08-22 重庆大学 红景天苷衍生物及其应用
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
CN114933619B (zh) * 2022-05-18 2024-03-01 上海科利生物医药有限公司 一类硫代糖苷列净类似物及其制备方法和应用
WO2024033288A1 (en) * 2022-08-12 2024-02-15 Société des Produits Nestlé S.A. Salicin derivatives as inhibitors of sglt2

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61233621A (ja) * 1985-04-10 1986-10-17 Agency Of Ind Science & Technol 肥満細胞脱顆粒抑制剤
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5444050A (en) 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
PL185372B1 (pl) 1995-06-29 2003-04-30 Texas Biotechnology Corp Inhibitory selektyny i kompozycja farmaceutyczna
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3065235B2 (ja) 1995-11-07 2000-07-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
DE19615576A1 (de) * 1996-04-19 1997-10-23 Beiersdorf Ag Verfahren zur Herstellung von Mono- und/oder Diglucosiden des Glabridins und deren Verwendung als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
DK0850948T3 (da) 1996-12-26 2002-07-29 Tanabe Seiyaku Co Propiophenonderivater og fremgangsmåde til fremstilling deraf
AU6024998A (en) 1997-01-15 1998-08-07 Glycomed Incorporated Aryl c-glycoside compounds and sulfated esters thereof
JPH10245391A (ja) 1997-03-03 1998-09-14 Dainippon Ink & Chem Inc ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
EP1042265A2 (de) 1997-12-12 2000-10-11 Ciba SC Holding AG O-derivate halogenierter diphenyletherverbindungen
US6486299B1 (en) 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6069238A (en) 1998-09-30 2000-05-30 Eli Lilly And Company Spirocyclic C-glycosides
KR100660738B1 (ko) * 2000-03-17 2006-12-22 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실록시 벤질벤젠 유도체, 그것을 함유하는의약조성물 및 그 제조중간체

Also Published As

Publication number Publication date
RU2269540C2 (ru) 2006-02-10
NO20024642L (no) 2002-11-21
DE60117012T2 (de) 2006-08-31
MXPA02009522A (es) 2003-05-14
BR0109326A (pt) 2004-03-30
KR100798203B1 (ko) 2008-01-24
EP1268502A1 (de) 2003-01-02
HUP0301513A3 (en) 2007-05-29
HK1049168A1 (en) 2003-05-02
ZA200207030B (en) 2003-12-02
HUP0301513A2 (hu) 2003-09-29
ES2258079T3 (es) 2006-08-16
AU4959801A (en) 2001-10-15
PL365176A1 (en) 2004-12-27
NO20024642D0 (no) 2002-09-27
JP2004500416A (ja) 2004-01-08
WO2001074834A1 (en) 2001-10-11
JP4986202B2 (ja) 2012-07-25
AU2001249598B2 (en) 2006-09-07
CN1275977C (zh) 2006-09-20
KR20030007488A (ko) 2003-01-23
EP1268502B1 (de) 2006-02-01
CN1437608A (zh) 2003-08-20
NZ520822A (en) 2005-03-24
CA2404373A1 (en) 2001-10-11
IL151473A0 (en) 2003-04-10
US6683056B2 (en) 2004-01-27
DE60117012D1 (de) 2006-04-13
US20020111315A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
ATE316976T1 (de) O-aryl glucosid sglt2 inhibitoren und verfahren
MEP13008A (en) C-aryl glucoside sglt2 inhibitors and method
TR200200986T2 (tr) C-aril glukozid SGLT2 önleyicileri.
UA88647C2 (ru) C-арилгликозидные ингибиторы sglt2 и процесс лечения с их использованием
ATE246197T1 (de) Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
DK0799209T3 (da) Sulfonamider
TR199801244T2 (xx) Herpese kar�� �zellikler ta��yan fenil tiyazol t�revleri.
CO5280198A1 (es) Inhibidores a base de pirrolidina fusionada con ciclopropilo de dipeptidil peptidasa iv y metodo
SE9202208D0 (sv) Vaevnadsfoerstaerkning
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
SE0003476D0 (sv) Compounds
WO2003059246A3 (en) Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
SE0004101D0 (sv) New use
ES2142490T3 (es) Ciclopeptolidos.
ATE321045T1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
ATE417059T1 (de) Verfahren zur herstellung hochreiner nicht toxischer toxinfragmente
BR9608633A (pt) Utilização de derivados de pirrolidina e do ácido (tercbutóxicarbonil-4 (fluoro-2 fenil)-2 fenil)2 tiazolidinil-3(2R.4R)-2 oxo-2etil)-3 ureído)-3 fenil)-2 propiónico no tratamento do alcoolismo
EA200000946A1 (ru) Кристаллическая форма пароксетина
DE60233353D1 (de) Verfahren zur behandlung von halitose
GT199700071A (es) Metodo de tratamiento de las plantas azucareras para mejorar el contenido de azucar.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1268502

Country of ref document: EP